|
|
Press Release Archive
 |
|
|
|
|
|
|
Transonic Systems forms Endosomatic Systems Inc.
Ithaca, NY; April 3, 2007
Endosomatic Systems Inc. Forms to Market Implantable Biotelemetry Systems. Biomedical Research
Measurement Innovations Corporation, parent company of Transonic Systems Inc., Ithaca, NY, is pleased to announce the formation of Endosomatic Systems Inc., successor to EndoSomatic Technologies LLC. Transonic Systems Inc. and other designated distributors will market the advanced Endosomatic biotelemetry systems worldwide.
Endosomatic Systems Inc. president Koullis Pitsillides remarks, “This is a milestone for Endosomatic. It will enable advanced biotelemetry solutions to become available to researchers who seek to acquire physiological data in unrestrained animals.” EndoSomatic Technologies has developed the first completely implantable biotelemetry system that measures Doppler blood flow, blood pressure and other physiological parameters. The system has been widely tested in many challenging environments in a variety of animals (sturgeon, alligator, pig, giraffe).
The Endosomatic implantable telemetry system will complement Transonic Systems’ existing PhysioGear I pocket telemetry system. Cornelis J. Drost, president of Transonic Systems Inc., comments, “We are excited by this fusion of technology and the formation of Endosomatic Systems Inc. This biotelemetry-focused company will allow us to respond to requests from Transonic customers for biotelemetry monitoring of other physiological parameters in addition to flow.”
The Endosomatic implantable system will be exhibited at the upcoming 2007 Experimental Biology meeting April 28 to May 2 in Washington, D.C. Full market release is planned for the fall of 2007. For more information, contact Transonic Systems Inc. at 607-257-5300 or www.transonic.com.
Transonic SystemsFiles for
Infringement of Its Hemodialysis Access Flow Measurement Patents
Ithaca NY, November 12, 2003.
Transonic Systems Inc. announced
today that it filed a lawsuit against Fresenius USA Inc. and Fresenius
Medical Care Inc. for infringement of Transonic's US patent numbers
5,685,989 and 6,514,419. These patents protect Transonic's "Krivitski
Method" of measuring access flow during dialysis, using blood line
reversal and indicator dilution principles. According to papers just
filed in Federal District Court in San Francisco, CA, Transonic claims
that the on-line clearance (OLC) access flow measurement which
Fresenius recently integrated in its 2008K Dialysis Delivery Machine
infringes the Krivitski measurement approach as protected under US
patent law.
According to Mr. Cornelis Drost,
President of Transonic: "We approached Fresenius several times to
attempt to avoid this dispute, and it is very unfortunate that
Fresenius has instead chosen to disregard our intellectual property
rights. Our patents protecting Dr. Krivitski's pioneering contribution
to the hemodialysis patient community are very important to the
company. We have spent millions of dollars in bringing this method to
market, and Transonic will vigorously enforce its patents to protect
its rights. Transonic realizes that the dialysance method has not been
independently validated, and we would not want to block scientific
inquiry. Researchers wanting to perform such independent validation
studies may contact Transonic for a temporary license for the duration
of those studies." Transonic is represented in this dispute by
intellectual property law firm Knobbe, Martens, Olson & Bear.
The blood line reversal method
of measuring access blood flow, which is the subject of the '989 and
'419 patents, was invented by Transonic's Senior Scientist Dr. Nikolai
Krivitski in 1994. His invention led to breakthrough improvements in
the management of stenotic disease in the hemodialysis access.
Approximately 300,000 USA patients have lost functionality of their
kidneys, and a well-functioning dialysis access (A/V shunt or fistula)
is their link to life as it facilitates hemodialysis. Research studies
using the Transonic ultrasound access flow monitor quickly revealed
that flow-based surveillance of the access, coupled with
minimally-invasive procedures to restore flow, would lead to reduced
patient morbidity and hospitalization and prolonged life of the
hemodialysis access shunt. The "Krivitski Method" was incorporated in
the "Dialysis Outcome Quality Initiative" guidelines published by the
National Kidney Foundation in 1997 as the preferred method for
surveillance of patients during their routine dialysis treatment.
Transonic manufactures and
sells a broad range of blood flow measurement devices for
intraoperative surgery, hemodialysis and biomedical research, and
provides embedded flow measurement solutions to manufacturers of
medical devices.
|
|
|
|
|
Transonic Systems Wins Court of
Appeals Ruling on Its Hemodialysis Access Flurementurement Patent
|
|
|
|
|
Ithaca NY, October 2 2003:
Transonic Systems Inc. announced today that the United States Court of
Appeals for the Federal Circuit issued a ruling in Transonic's patent
dispute with Non-Invasive Medical Technologies Corporation (dba
HemaMetrics). Transonic prevailed on all counts. Most notably, all
critical claim terms of Transonic's US patent No. 5,685,989 have now
been given a broad scope. According to Mr. Cornelis Drost, President of
Transonic Systems: "The scope of Transonic Systems '989
patent has now been fully reviewed by the US Court of Appeals and the
patent has received a very broad interpretation. Based on this
and a previous appellate court ruling, we believe that our access flow
measurement patent covers all indicator dilution-based access
flow measurement approaches using blood line reversal during
hemodialysis. Based on this ruling, Transonic expects to succeed
in obtaining a judgment against HemaMetrics that the saline injection
and Delta-H access flow measurement approaches offered in connection
with its Crit-Line device infringe the '989 patent. Transonic
Systems Inc. is representated in this dispute by intellectual property
law firm Knobbe, Martens, Olson & Bear.
The blood line reversal method
of measuring access blood flow, which is the subject of the '989
patent, was invented by Transonic's Senior Scientist Dr. Nikolai
Krivitski in 1994. His invention led to breakthrough improvements
in the management of stenotic disease in the hemodialysis access.
Approximately 300,000 USA patients have lost functionality of their
kidneys, and a well-functioning dialysis access (A/V shunt or fistula)
is their link to life as it facilitates hemodialysis.
Research studies using the Transonic ultrasound access flow monitor
quickly revealed that flow-based surveillance of the access, coupled to
minimally-invasive procedures to restore flow, would lead to reduced
patient morbidity and hospitalization and prolonged life of the
hemodialysis access shunt. The "Krivitski Method", with more than
one hundred publications, was incorporated in the "Dialysis Outcome
Quality Initiative" guidelines published by the National Kidney
Foundation in 1997 as a preferred method for surveillance of patients
during their routine dialysis treatment.
Transonic Systems manufactures
and sells a broad range of blood flow measurement devices for
intraoperative surgery, hemodialysis, biomedical research, and provides
embedded flow measurement solutions to manufacturers of medical devices.
|
|
|
|
|
|
|
Transonic
Systems Inc. Celebrates 20th Year Anniversary
|
|
Press Release July
1, 2003
Transonic Systems Inc., global
manufacturer of biomedical flow measurement equipment, celebrated its
20th anniversary July 1, 2003 at its international headquarters at 34
Dutch Mill Road. Founded twenty years ago by Cornelis Drost, author of
a transit time ultrasound patent to measure blood flow developed at
Cornell University, the company has grown to a multi-million dollar
ISO9001 certified manufacturer of flow measurement products with sales
and distribution throughout the world.
As the recognized global biomedical flow measurement leader, Transonic
products support advances in medical care and basic research. Over 90%
of surgeries involve the restoration of blood flow, and Transonic surgical flowmeters are used by cardiac,
transplant and neurosurgeons to improve their surgical outcomes. Transonic flow modules are part of cardiac
bypass pumps and cardiac assist devices such as the DeBakey LVAD, a
bridge-to-transplant device for patients with heart
failure. New medical treatments, drugs and surgeries are tested with Transonic's gold standard
research flowmeters. The Transonic Flow-QC Hemodialysis
Monitor
enhances the quality of care for hemodialysis patients throughout the
world.
At the celebration, president Drost recognized the gathered employees,
notably the first three Transonic employees Gary Thomas, Jim Olsefski
and Jan Milanowski, and all the employee families for their dedication
and perserverance. Special tribute was paid to company director Dr.
Alan Dobson, professor emeritus NYS College of Veterinary Medicine at
Cornell University, for fostering the high scientific standards upon
which the company is based. Drost acknowledged Dr. Dobson's
contribution to the company's world-class research and development
team, which has attracted numerous National Institutes of Health
SBIR/STTR grants over the years and was awards the prestigious 2000
National Tibbetts Award.
President Drost concluded, "Our 20-year history makes us look to the
future with confidence as we continue to make products that will
advance medical care. In the process, we will continue provide a home
to an ever-growing number of employees." Transonic Systems Inc. is a
fully owned subsidiary of Ithaca-based Measurement Innovations
Corporation with sales and marketing subsidiaries in the Netherlands and Japan.
|
|
|
|
|
|
NIH Funds New
Laser Doppler Device to Monitor Diabetic Microcircualtion
|
|
Press Release June
25, 2003
Transonic Systems Inc., global
manufacturer of biomedical flow measurement equipment, received word today
that the company will receive $100,000 as Phase I SBIR funding from to
redesign a laser Doppler flowmetering system and to develop algorithms
to detect the onset of microcirculatory problems in diabetics.
The new laser Doppler monitoring system
will enable research studies of the deficiencies in peripheral blood
perfusion and neurological control of perfusion during the early stages
of diabetes. The studies could eventually produce a simple, noninvasive
test for early detection of diabetes using the monitor.
During
Phase One, Transonic Systems will build prototype hardware to
demonstrate the feasibility of using high resolution laser Doppler
flowmetry under low flow conditions with spectral analysis software
optimized for low-frequency skin perfusion measurement. Collaborators
Drs. Thomas L Smith and Francis Walker at Wake Forest will validate the
instrument in a clinical setting. Prospective Phase II funding would
support studies with diabetic populations by three independent research
groups and finalize the commercial monitor.
The
need for such a device is compelling, for diabetes is quickly become an
American health crisis with 800,000 new cases diagnosed each year. As
life expectancy and obesity increase, the incidence of diabetes is also
expected to increase.Currently diabetic-related microcirculation
problems result in 200,000 cases of foot ulcers and 80,000 amputations
per year in the United States alone. Screening could lead to early
detection, treatment and prevention.
|
|
|
|
|
|
Transonic
Systems Inc. Enhances Quality of Care for Hemodialysis Patients with
Shipment of 1000th Flow-QC Hemodialysis Monitor
|
|
Press Release -March
27, 2003
Transonic Systems Inc., global manufacturer of biomedical flow
measurement equipment, announces shipment of its 1000th Flow-QC
Hemodialysis Monitor to Dialysis Clinics Inc. (DCI) in Carlsbad, NM
where it will enhance the quality of care for their hemodialysis
patients. The Flow-QC Hemodialysis Monitor allows hemodialysis clinics
to routinely screen patients during their dialysis treatments for
vascular access patency, dialysis adequacy and cardiac output.
For hemodialysis patients, their
vascular access is their link to life. This surgically created
connection between an artery and vein enables access to kidney failure
patients' blood so that it may be cleansed. The vascular access, which
is the patient's link to life, often narrows and can shut off
completely. The United States Renal Data System (USRDS) reports that
hemodialysis access failure is the second most frequent cause of
hospitalization among hemodialysis patients. Medicare costs for these
hospitalizations exceed $1 billion annually.
Transonic's Flow-QC Monitor has
given the nephrologist a new tool to track the progression of stenotic
disease within the vascular access. The dialysis staff can proactively
intervene to extend the life of the access without hospitalizing the
patient for major surgery.
Thomas Depner, MD, Department of
Medicine, UC Davis, comments, "The Transonic Flow-QC Hemodialysis
Monitor has benefited numerous dialysis-dependent patients by reducing
and, in many cases, eliminating the agony of a clotted AV graft or
fistula, thereby facilitating correction of access stenosis on an
elective basis that prevents missed dialyses and the need for placing
temporary catheters." Dr. Depner also notes, "The success of the
Transonic Hemodialysis Flow-QC Monitor is largely due to the dedication
of Nikolai Krivitski, PhD, DSc and his coworkers who persistently
sought feed-back from physicians, nurses and other health care
providers in an ongoing effort to increase the instrument's utility."
Dr. Krivitski, senior scientist
at Transonic Systems, combined classic dilution technology with
Transonic Systems' ultrasound transit-time technology to measure blood
flow parameters during dialysis. Since publication of the Kriviski
Method® in 1995 in collaboration with Dr. Depner, an unprecedented
400 publications have reported on the use of Transonic Systems' Flow-QC
Hemodialysis Monitor and the resulting improvements in medical care.
The National Kidney Foundation
embraced the enhanced standard of care provided by the Transonic
Flow-QC Hemodialysis Monitor by recommending its use in its Kidney
Dialysis Outcomes Quality Initiatives (K/DOQI) for monthly vascular
access surveillance. The National Institutes of Health (NIH) continues
its support of Dr. Krivitski's innovations for medical diagnosis, most
recently with a grant for cardiac output measurements in children.
As Transonic Systems Inc. ships
its 1000th Hemodialysis Monitor, it is proud of its role in reducing
the necessity for hospitalizations for hemodialysis patients and
advancing the continued improvement in quality of care. Cornelis Drost,
president of Transonic Systems comments, "We are very pleased with this
milestone. It means that an estimated 80,000 patients worldwide receive
the benefits of the proactive disease management made possible by Dr.
Krivitski's invention. Much of the credit goes to our clinical
researcher collaborators who were quick to demonstrate its efficacy and
money savings, and the National Kidney Foundation who embraced vascular
access monitoring in its 1997 DOQI Guidelines."
Mr. Drost continues: "Our
technology has been well received in a number of foreign
countries: 80% of the clinics in Holland, 75% in Canada, 30% in
France have integrated our hemodialysis monitor into their Vascular
Access Management Programs. A medical reimbursement (CPT)
code has been established in the USA, and leading researchers at the
Renal Physicians Association continue to accumulate data to persuade
the Center for Medicare & Medicaid Services (CMS) to reimburse for
these tests, and thus extend the patient benefits to our full dialysis
patient community."
|
|
|
|
|
|
National Institutes of Health
(NIH) Awards Transonic Systems Grant to Continue Development of
Technology to Measure Cardiac Output in Intensive Care Unit Children
and Neonates
|
|
|
|
|
April, 2003, Ithaca, NY — The
National Institutes of Health has awarded Transonic Systems $750,000 to
continue its development of a minimally-invasive cardiac output monitor
for to measure cardiac output routinely in pediatric and neonatal
patients in intensive care units. At present there is not a safe,
feasible way to measure the cardiac output (the volume of blood that
the heart pumps during one heartbeat) in children. The grant will fund
collaborative clinical research with Robert K. Kanter, MD, Upstate
Medical University Hospital, Syracuse, NY; Thomas H Shaffer, Thomas
Jefferson University, Philadelphia, PA amd Shekhar Venkataraman, MD,
Children's Hospital of Pittsburgh. Nikolai Krivitski, PhD, DSc, and his
team at Transonic Systems Inc. will head the investigation.
The study will continue
development of a quick, simple and accurate system which uses a small
amount of innocuous isotonic saline which is introduced into the
patient's blood to be used as an indicator from which to calculate
cardiac output. Already demonstrated to be both useful and accurate in
preliminary bench, animal and clinical studies, the technology does not
require any contact with the patient's blood or cardiac
catheterization, the current method for assessing cardiac output in
adults. The new method can also identify a septal defect in the child
and can measure blood volume in the heart, lungs and great vessels such
as the aorta.
Specific objectives of the
proposal are to develop new sensors to improve the capability of the
existing system, to increase the data archive of cardiac output
dilution measurements, to validate the system against thermodilution
cardiac measurements, the most widely used method to measure cardiac
output in adults in intensive care units. The new system, when
completed and validated, will offer an attractive alternative to the
high risk and cost associated with heart catheterization when measuring
cardiac output by thermodilution.
|
|
|
|
|
Transonic Systems Inc. & The
National Institutes in Health (NIH): Partners in Flow Measurement
Innovations Which Improve the Quality of Patient Care
|
|
|
March, 2003, Ithaca, NY — Since
1995, Transonic Systems Inc. has been the recipient of NIH basic
research grants to further the capabilities of flow measurement in both
the animal laboratory and clinical settings. The research and
development afforded by these grants have resulted in new products for
the improvement of quality care for patients. The grants constitute a
marriage of business and academia with university collaborators being
integral to the research process.
One of the first grants received
by Transonic Systems produced the first comprehensive Tools and
Techniques to Measure Flow and Pressure in Mice in collaboration
with Thomas L. Smith, PhD and Michael F. Callahan, PhD of Wake Forest
Health Science Center, Winston-Salem, NC. Another grant, The
Measurement of Hemodialysis Access Flow and Recirculation
accelerated the introduction of the Transonic Flow-QC Hemodialysis
Monitor which saves lives by predicting the onset of critical stenosis
in vascular accesses.
More recently, Transonic
Systems has been awarded Phase II of a grant: A Flowmeter with
Telemetry for Chronic Animal Studies. For a complete listing of
Transonic NIH grants and collaborators, click here .
|
|
|
|
 |
|
|
|
|
Transonic Systems Inc. & The
National Institutes in Health (NIH): Partners in Flow Measurement
Innovations Which Improve the Quality of Patient Care
|
|
|
|
|
March, 2003, Ithaca, NY — Since
1995, Transonic Systems Inc. has been the recipient of NIH basic
research grants to further the capabilities of flow measurement in both
the animal laboratory and clinical settings. The research and
development afforded by these grants have resulted in new products for
the improvement of quality care for patients. The grants constitute a
marriage of business and academia with university collaborators being
integral to the research process.
One of the first grants received
by Transonic Systems produced the first comprehensive Tools and
Techniques to Measure Flow and Pressure in Mice in collaboration
with Thomas L. Smith, PhD and Michael F. Callahan, PhD of Wake Forest
Health Science Center, Winston-Salem, NC. Another grant, The
Measurement of Hemodialysis Access Flow and Recirculation
accelerated the introduction of the Transonic Flow-QC Hemodialysis
Monitor which saves lives by predicting the onset of critical stenosis
in vascular accesses.
More recently, Transonic
Systems has been awarded Phase II of a grant: A Flowmeter with
Telemetry for Chronic Animal Studies. For a complete listing of
Transonic NIH grants and collaborators, click here .
|
|
|
|
|
U.S. Senate Receives Testimony
Where Transonic Systems Nanoprobe Project Is Cited As NIH-STTR Success
Story.
|
|
|
|
|
|
Press Release -
December 2002
In written testimony to the
U.S. Senate, Jo Anne Goodnight, Coordinator of the Small Business
Innovation Research (SBIR) and Small Business Technology Transfer
(STTR) Programs at the National Institutes of Health (NIH) choose the
development of Transonic Systems} nanoprobes as the prime example of an
STTR success story which has "resulted in significant improvements to
our nation}s health and in increased productivity of other
researchers."
She reported that Transonic
Systems has "used NIH STTR funding to develop tools and techniques
to measure flow and pressure in mice. These measurements will help
researchers to learn more about diseases, such as hypertension.
Transonic Systems saw a need in the research community to have such
flow measurement devices for studies in mice. As transgenic mice have
become a prime model for physiology studies, researchers needed smaller
measurement devices for flow and pressure to conduct acute studies and
chronic studies of conscious animals. Transonic Systems developed these
devices with great success. The company was able to develop and
validate a cardiac output flow for acute and chronic studies. Transonic
also developed (at the Cornell nanofabrication facility) revolutionary
new manufacturing methods to make even smaller probes that researchers
need for hypertension studies."
"The development of the
miniaturized flow probe marks the first time that anyone has ever been
able to chronically measure kidney blood flow in a conscious,
exercising mouse. Since the kidneys control blood pressure in both
humans and mice, these blood flow measurements will help researchers
understand how diet and experimental drugs can alter kidney blood flow
and hence kidney function, leading to improved medicines for Americans
suffering from high blood pressure/hypertension."
For complete text and pictures
of testimony click on: http://www.hhs.gov/asl/testify/t010621.html
|
|
|
|
|
|
Transonic Systems Inc. Partners
with Nihon-Kohden Corp.-Japan to Market Transonic Surgical
Flowmetering Products in Japan
|
|
|
|
|
|
Press Release - November
2002
Transonic Systems Inc. is
pleased to announce that Nihon Kohden, Tokyo, Japan has received
medical device approval to sell Transonic HT300-Series surgical
flowmeters and flowprobes in Japan. This removed the final obstacle
that prevented Nihon Kohden's sale of Transonic
medical products in Japan and
finalized a distributor agreement between Transonic Systems, Ithaca, NY
and Nihon Kohden, Japan.
After a historic meeting this
month with Mr. Kazuo Ogino, president and CEO of Nihon Kohden in Tokyo,
Japan, Cornelis Drost, founder and president of Transonic Systems Inc.
remarked, "This is one of the most important agreements we've
reached in the history of Transonic Systems. In the medical
instrumentation market, Nihon Kohden, an $800,000,000 company, is the
Hewlett Packard of the Far East. It is a very stable company with a
superior reputation and 120 direct sales offices throughout Japan."
Kohden Engineering, a division
of Nihon Kohden, will now import, market, sell and distribute the
Transonic ultrasonic transit-time product line in place of the
discontinued Nihon Kohden electromagnetic flowmeter. Because the
division has already had flowmetering products, Kohden Engineering
understands Transonic technology thoroughly and Mr. Drost is optimistic
that the new Transonic-Nihon Kohden partnership will serve as an
important model in which the company can develop its external
marketing, service and support structures and procedures.
|
|
|
|
|
|
Transonic Technology
(ultrasound indicator dilution) to Measure
Access Flow Is Integral to Dialysis Access Consortium (DAC) Study
|
|
Press Release - October
2002
In a major Dialysis Access
Consortium study to find treatments to prevent vascular access failure,
a leading cause of morbidity and expense for people on hemodialysis,
Transonic Systems gold standard indicator dilution technology will be
used to measure access flow rates to detect a hemodynamically
signifcant stenosis before it leads to access thrombosis. The National
Institutes of Health (NIH)-funded study is expected to enroll a total
of 1228 subjects over three years with an additional followup of one
year. Access failure results from myointimal hyperplasia leading to
access stenosis and thrombosis. The randomized, double-blind,
placebo-controlled multi-center study is designed to test whether the
sustained release of dipyridamole and aspirin will prevent access
failure in persons who receive a new upper arm synthetic arteriovenous
graft.
|
|
|
|
|
|
Press Release - September
2002
NIH Extends Funding for Flow
Measurement during Angioplasty with Phase II Grant
|
|
The National Institute of
Diabetes and Digestive and Kidney Diseases of the National Institutes
of Health has extended its support of the development and evaluation of
a novel flow measurement catheter for use during angioplasty on ESRD
patients with a $750,000 Phase II award through 2004.
The project entitled "Flow
Measurement at Dialysis Access Salvage" seeks to develop and clinically
validate a catheter-based "Angioflow Meter" - a device that measures
blood flow during angioplasty of PTFE grafts and native fistulae. The
proposed device will aid the radiologist in evaluating angioplasty in
terms of blood flow rate. It will provide on-the-spot monitoring of the
efficacy of angioplasty interventions, will help locate hemodynamically
significally stenoses and will signal when the intervention goal of
restoration of adequate blood flow is achieve.
Phase I of the project confirmed
the technical feasibility of measuring flow during angioplasty. The new
funding will continue the clinical testing of the device in preparation
for its marketing.
The funding is an example of
Transonic Systems leadership role in the innovation of new flow
measurement products which enhance the quality of patient care
throughout the medical community.
|
|
|
|
|
|
Press Release - July
2002
New Information Added to
Research on Website.
|
|
The research section of
Transonic.com has become more comprehensive with an updated Research Products page,
with over 80 new links to Transonic's gold standard measurement
capabilities with the new 400-Series Flowmeter (see
our new on-line 400-Series brochure); the
industry standard T106/T206 flowmeter; the T110 tubing flowmeter line,
and BLF21 laser Doppler tissue perfusion meters. Links are to features,
benefits, specifications, manuals, quick references guides and
brochures. Also check out the newly updated listings of speciality
applications under Research Support.
|
|
|
|
|
|
Press Release - August
2002
Transonic Systems Publishes Cardiac Function Assessment
Guide
|
|
The 32-page guide entitled
"Cardiac Function Assessment during Hemodialysis - Transonic
Flow-QC." presents an overview of cardiac functioning monitoring
for ESRD during their dialysis treatment. This new capability comes at
a time when the devastating effects of cardiovascular disease in the
ESRD population is gaining recognition. As the leading cause of ESRD
morbidity and mortality (10 to 20 times the rate of the general
population), cardiovascular disease has reached epidemic proportions
within the hemodialysis population. Transonic Cardiac Function
(Flow-QC) Monitoring provides clinicians with a way to integrate
cardiac function studies into a clinic's treatment protocols, thereby
forestalling the consequences of CVD. Available in hardcopy (click here) from
Transonic Systems Inc. or in pdf
format
above
|
|
|
|
|
|
Transonic
Innovation...in the News
Transonic Systems Introduces
Autoclavable "flash" Flowprobes
|
|
Press Release - March-August
2002
Transonic Systems takes the
flowprobe engineering one step further by introducing the first
autoclavable flowprobes. The reusuable steam sterilizable flowprobes
are available in sizes 2, 3, & 4 mm, in two styles: one with an
elongated handle for ease of use in coronary artery bypass grafting
surgery, and another shorter handle style designed for vascular surgery
but which can be used interchangeably. The flowprobes are also
sterilizable by standard cold EO or STERRAD. Click here for
views of the new flowprobes.
|
|
|
|
|
|
Press Release - May
2002
Website Site Expands: now
includes dedicated Transonic Systems Europe B.V.
pages.
|
|
Clicking on Transonic Systems
Europe B.V. on either the Customer Service page or on Transonic Systems
page now directs the viewer to a dedicated Transonic
Systems Europe B.V. page
with listings of staff, upcoming European congresses, distributors and
representatives in various countries in the three administrative
regions.
|
|
|
|
|
|
Press Release - May
2002
New Web Links Showing Probe
Pictures / Recommendations
|
|
To enhance Customer Service for
our research customer, new links have been added to the Research site.
Now when one clicks on one of the species/vessel applications on the
Research Home page, the link takes one first to the recommended sized
probe for that application. The probe size is then linked to a picture
of that probe.
|
|
|
|
|
|
Press Release - May
2002
Transonic Database of Publications Approaches 3,000.
|
|
Transonic maintains a database
of publications which cite use of transit-time ultrasound technology to
measure flow. This database, available via SEARCH on
this web site recently surpassed 2300 papers representing over 250
different applications. Transonic Systems also maintains a database of
ultrasound dilution papers and abstracts, now over 250, and laser
Doppler publications (over 125).
|
|
|
|
|
|
|
|
|
|
Press Release - April
2002
Transonic Systems Publishes Flow-based
Intraoperative Graft Patency Assessment Handbook
|
|
Now available in hardcopy (click
here) or in pdf
format on this website is
the 80-page handbook which presents transit time ultrasound for
assessment of the patency of coronary bypass grafts during on-pump or
off-pump CABG. The handbook includes the physiology behind the flow
measurements, the protocol for making the measurements, waveforms from
over 80 representative grafts, case studies and an appendix of
measurement modalities, technology and
references.
|
|
|
|
|
|
|
|
|
|
Press Release - March
2002
Mouse Instrumentation
Tutorial at Experimental Biology 2002
Monday, April 22, 2002 8-9 am Rm
R01
|
|
Scientists will present their
instrumentation methods and considerations for hemodynamic data in the
murine model including protocols for direct blood flow measurements
using miniaturized 1.5 mm ultrasonic transit-time flowprobe for the
mpouse ascending aorta and new 0.5 - 0.7 mm "Nanoprobes" for
the mouse renal artery. Also presented will be ultrasound dilution, a
new technique to determine cardiac output by saline dilution of blood
flowing through an extracorporeal flowprobe.
Program: 8 am: Use of Anesthetic Agents in Murine
Hemodynamic Protocols, T. Smith; 8:15 am: Validation of Cardiac
Output Measurements in Conscious Mice, B. Janssen; 8:30:
Cardiac Output in Mice by Ultrasound Dilution Technique, M Callahan;
8:45: Q &
A
|
|
|
|
|
|
Press Release - March
21, 2002
Transonic Reo-Cath™ Monitor
Facilitates Interventions
|
|
March 21, 2001 - The FDA today
cleared the Transonic Reo-Cath™
Monitor for measurement of volume blood flow through an A-V access. The
measurement uses gold standard Transonic volume flow technology to
measure blood flow during angioplasty. A small injection of saline is
introduced through a thermal dilution catheter introduced through the
standard sheath. Access shunt flow is automatically displayed on the
Reo-Cath™ monitor in ml/min.
The Reo-Cath
™
monitor is clinically significant because it gives interventional
radiologists quantitative flow data by which to proactively manage
their intervention. The measurements identify dysfunctional accesses,
provide baseline data for follow-up tests and enable greater control
and quicker response in procedure management. "Utilization of the
flowmeter to measure intra-graft blood flow during the angioplasty
procedure was beneficial for assessing the hemodynamic significance of
stenoses and to determine the success of the dilatation. In conclusion,
the Reo-Cath™ is a useful and accurate endovascular device for
measuring blood flow during interventional procedures."1
For information:
Transonic Systems, Inc. Tel: 1-800-353-3569; Fax: 607-257-7256; 1Vesely
et al, "Preliminary Experiences Using Intravascular Blood Flow Monitor
(IBFM) during Vascular Access Angioplasty," JASN Abstracts, Vol. 10, p.
221A, 1999.
HD10T
|
|
|
|
|
|
Transonic
Innovation...in the News
Transonic Systems' Partner,
Micro-Med, Authors Study Using Flow Data Achieved with Customized
Transonic Flow System
|
|
First of kind study reveals
insight into how a continuous flow VAD responds to a Chronic Heart
Failure patient's exercise needs
HOUSTON-March 13, 2002- MicroMed Technology, Inc.
announced today the completion of a two-year waveform analysis
involving more than 100 patients to determine the most efficient
control of a continuous flow VAD to increase blood flow and avoid
ventricular suckdown as heart failure patients recover and want more
strenuous exercise.
Over the course of two years,
MicroMed Technology, in collaboration with the University of Vienna,
Austria, has developed a physiologic algorithm using a comprehensive
database of 1000+ snapshots of over 100 patients' VAD flow waveforms.
These were collected using the sophisticated flow probe data
acquisition system, part of the DeBakey VAD® system ...
Click here to
view full press release by MicroMed
|
|
|
|
|
|
Press Release - September
29, 2001
NIH Extends Funding for Flow
Measurement during Angioplasty
|
|
The National Institute of
Diabetes and Digestive and Kidney Diseases of the National Institutes
of Health has extended its support of the development and evaluation of
a novel flow measurement catheter for use during angioplasty on ESRD
patients. Transonic Systems was notified today to an award for $54,700
in extension funds and an extension of the grant period through 2002.
The project entitled "Flow
Measurement at Dialysis Access Salvage" seeks to develop and clinically
validate a catheter-based "Angioflow Meter" - a device that measures
blood flow during angioplasty of PTFE grafts and native fistulae. The
proposed device will aid the radiologist in evaluating angioplasty in
terms of blood flow rate. It will provide on-the-spot monitoring of the
efficacy of angioplasty interventions, will help locate hemodynamically
significally stenoses and will signal when the intervention goal of
restoration of adequate blood flow is achieve.
Phase I of the project confirmed
the technical feasibility of measuring flow during angioplasty. The new
funding will continue the clinical testing of the device in preparation
for its marketing.
The funding is another example
of Transonic Systems leadership role in the innovation of new flow
measurement products which enhance the quality of patient care
throughout the medical community.
|
|
|
|
|
|
Press Release - September
24, 2001
Thirty-plus ASN'01 Abstracts
Cite Transonic
|
|
Again, Transonic Systems will be
well represented at the upcoming annual American Society of Nephrology
convention with over 30 posters.
Of note is a study, "Early
Detection of Arterio-Venous Graft (AVG) Stenosis," performed Kaiser
Permanente, LA, CA. Nineteen patients were screened by four methods for
early detection of AVG stenosis. Screening methods included: venous
pressure of over 200 mm Hg; recirculation measurement of 10% or higher,
Transonic hemodialysis monitoring of vascular access flow of less then
800 ml/min and angiogram study with graft stenosis of 50% or more. Of
the 19 patients screened within a one week period, three had venous
pressure of more then 200 mmHg; recirculation was normal in all
patients; HD monitoring revealed vascular access blood flow of less
then 800 ml/min in 10 patients with stenosis of 50% confirmed by
angiogram. Angiography detected a total of 16 stenoses greater than
50%. The clinicians concluded that, while venous pressure and
recirculation measurements are easy to perform, they are poor early
detectors of graft stenosis. Transonic hemodialysis monitoring is more
accurate with 62.5% accuracy compared to angiography and no false
positives. They suggest that their colleagues consider the Transonic
HD01 hemodialysis monitor as a non-invasive method for early detection
and monitoring of AVG stenosis.
Mak, J., Terasaki, K., Abcar,
A.C., Der, D., Kim, H., Yeoh, H., Rasgon, S., Idroos, M., "Early
Detection of Arterio-Venous Graft (AVG) Stenosis," ASN Abstracts 2001.
|
|
|
|
|
|
Press Release - August
29, 2001
Kidney International
Study Ties Vascular
Access Blood Flow Monitoring with Reduction in Access Morbidity and
Costs.
|
|
Researchers from the Department
of Nephrology, Vanderbilt University Medical Center, Dialysis Clinics
Inc. and Renal Care Group of Nashville, TN USA published a three-phase
study which compared the clinical and financial impact of vascular
access blood flow monitoring with the Transonic HD01 to
detect access dysfunction. The research team lead by Patricia McCarley,
investigated the effect of vascular access blood flow monitoring
(VABFM) on thrombosis-related events, compared to the effect of dynamic
venous pressure monitoring (DVPM), and that of no monitoring for
vascular access stenosis.
The researchers conclude, "The
results of this study strongly suggest that access blood flow
monitoring for early detection of vascular access malfunction coupled
with preventative intervention reduces the vascular access thrombosis
rate as well as associated charged when compared with no monitoring or
dynamic venous pressure monitoring in chronic hemodialysis patients.
The overall benefit from this approach provides an overall cost cutting
of 49% compared with no monitoring and 54% compared with dynamic venous
pressure monitoring. The beneficial effects as are observed as
decreased in the total number catheters inserted, thromboectomies, new
accesses placed, and missed treatments, suggesting additional medical
advantage to patients. ...We conclude thaty vascular access blood
monitoring along with preventive interventions should be the standard
of care in chronic hemodialysis patients.
To read more click here:
|
|
|
|
|
|
|
|
|
|
Press Release - August
28, 2001
Satellite Dialysis Opens New,
Expansive Sunnyvale Clinic to Serve 150 Dialysis Patients with
Transonic Flow-QC Access Monitoring for Better Patient Care
|
|
Satellite's Heathcare's CEO Mark
Burke says, "We are proud to offer tyhis state-of-the-art,
patient-friendly center to forward the guiding mission of Satellite
Heathcare... And, making this center truly unique to the Sunnyvale
community is the fact that it is the only dialyiss center in the area
to offer Transonic
Access Monitoring."
|
|
|
|
|
|
Press Release - August
20, 2001
Transonic Systems Innovation
Continues
Transonic Systems leadership in
flow measurement technology continues with the recent issurance of the
following patents:
|
|
Patent
|
Title
|
Inventor(s)
|
Assignee
|
|
6,041,246
|
Single Light Sensor Optical
Probe for Monitoring Blood Parameters and Cardiovascular Measurements
|
Krivitski, N.M.
Starostin, D.M.
|
Transonic Systems, Inc., Ithaca,
NY
|
|
6,036,645
|
Ultrasonic Probe
|
Drost, C., Shkarlet, Y.,
Kopychev, A., Ostergren, L., Sergeeva, I.
|
Transonic Systems, Inc., Ithaca,
NY
|
|
6,153,109
|
Method and Apparatus to Measure
Blood Flow Rate in Hemodialysis Shunts
|
Krivitski, N.M.
|
Transonic Systems, Inc., Ithaca,
NY
|
|
6,061,590
|
Method and Apparatus for
Predicting Intradialytic Morbid Events Through the Monitoring of a
Central Blood Volume
|
Krivitski, N.M.
|
Transonic Systems, Inc., Ithaca,
NY
|
|
6,155,984
|
Method and Apparatus for
Measuring Cardiac Output through an Arterial Cannula
|
Krivitski, N.M.
|
Transonic Systems, Inc., Ithaca,
NY
|
|
6,098,466
|
Ultrasonic Flow Sensor
Incorporating Full Flow Illumination
|
Shkarlet, Y.,
|
Transonic Systems, Inc., Ithaca,
NY
|
|
|
|
|
|
|
|
|
|
Press Release - September
2000
Transonic
Systems Receives Tibbetts Award
|
|
Transonic
Systems received the Fifth Annual Tibbetts Award in Washington, DC on
October 3, 2000. The award from the Small Business Administration
recognizes the company's contribution as a "Model of Excellence" for
the Small Business Innovation Research (SBIR) program. It recognizes
Transonic Systems for its invention and development of the Flow-QC
Hemodialysis Monitor which measures vital blood flow parameters while a
patient is undergoing dialysis.
For more information about the
award click Tibbetts
Award.
|
|
|
|
|
|
|
|
|
